<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>267</serviceExecutionTime><Trial id="183332"><TitleDisplay>Survey of Lipid Goal Attainment and Mortality in Patients With High Cardiovascular Risk in Thailand</TitleDisplay><TitleOfficial>Lipid-lowering Therapy in Patients With High Cardiovascular Risk and Their Three-year Mortality Rate in General Practice in Thailand</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00684151</Identifier><Identifier type="Organisational Study">NIS-CTH-DUM-2007/1</Identifier></Identifiers><Indications><Indication id="584">Lipid metabolism disorder</Indication></Indications><BiomarkerNames><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="584" type="ciIndication"><TargetEntity id="10061227" type="MEDDRA"></TargetEntity><TargetEntity id="D052439" type="MeSH"></TargetEntity><TargetEntity id="-386237446" type="omicsDisease"></TargetEntity><TargetEntity id="2898" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>44</NumberOfSites><CompaniesSponsor><Company id="14190">AstraZeneca plc</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>1240</PatientCountEnrollment><PatientCountEvaluable>1240</PatientCountEvaluable><DateStart>2008-04-30T00:00:00Z</DateStart><DateEnd type="actual">2011-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-06-09T10:43:24Z</DateChangeLast><DateAdded>2014-05-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Khon Kaen University</Affiliation><Name>Bandit Thinkhamrop, Ph.D</Name></Contact><Contact type="Scientific contact"><Affiliation>Khon Kaen University</Affiliation><Name>Songkwan Silaruks, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Evidence of high cardiovascular risk&lt;/li&gt;&lt;li&gt;Dyslipidemic currently being treated with the same therapy for at least 3 months&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Recent major trauma (within 12 weeks)&lt;/li&gt;&lt;li&gt;Recent surgery requiring anesthesia including coronary bypass graft (within 12 weeks)&lt;/li&gt;&lt;li&gt;Acute or abrupt change (within 1 month) in usual diet&lt;/li&gt;&lt;li&gt;Pregnancy, breast-feeding currently, or postpartum within the last 6 months&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>LDL-cholesterol</Description><Timeframe>June 2008</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Survival</Description><Timeframe>June 2011</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study was to evaluate lipid-lowering therapy in patients with high cardiovascular risk and their three-year mortality rate in general practice in Thailand.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results were published in July, 2011. 	As defined by the NCEP guidelines, a total of 633 of 1240 patients achieved the LDL-C goal levels. When compared with the high risk and moderate risk group, the lowest percentage was achieved by the very-high-risk group (54.2 versus 47 versus 11.6%, respectively). LDL-C goals in males and females were reported as 55.6 and 48.9%, respectively (p = 0.029) [&lt;ulink linkType="Reference" linkID="1550633"&gt;1550633&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with high cardiovascular risk who have been treated with lipid-lowering drugs at least 3 months would be enrolled and their lipid levels would be monitored.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who were treated with statins for a minimum of 3  months were enrolled for the study [&lt;ulink linkType="Reference" linkID="1550633"&gt;1550633&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Thailand"><Sites><Site><Name>Research Site</Name><Address1>Ban Pong</Address1><Address2>Ratchaburi</Address2><CountrySubDivision>Ratchaburi</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Hatyai</Address1><Address2>Songkhla</Address2><CountrySubDivision>Songkhla</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Kannayao</Address1><Address2>Bangkok</Address2><CountrySubDivision>Bangkok</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Ang Thong</Address2><CountrySubDivision>Ang Thong</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Ayutthaya</Address2><CountrySubDivision>Ayutthaya</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Chachoengsao</Address2><CountrySubDivision>Chachoengsao</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Chainat</Address2><CountrySubDivision>Chainat</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Chantaburi</Address2><CountrySubDivision>Chantaburi</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Chiang Mai</Address2><CountrySubDivision>Chiang Mai</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Chumphon</Address2><CountrySubDivision>Chumphon</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Kamphaeng Phet H</Address2><CountrySubDivision>Kamphaeng Phet H</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Kanchanaburi</Address2><CountrySubDivision>Kanchanaburi</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Krabi</Address2><CountrySubDivision>Krabi</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Lampang</Address2><CountrySubDivision>Lampang</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Lamphun</Address2><CountrySubDivision>Lamphun</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Lopburi</Address2><CountrySubDivision>Lopburi</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Mahasarakarm</Address2><CountrySubDivision>Mahasarakarm</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Nakorn Nayok</Address2><CountrySubDivision>Nakorn Nayok</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Nan</Address2><CountrySubDivision>Nan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Nokhon Si Thammarat</Address2><CountrySubDivision>Nokhon Si Thammarat</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Nokorn Pathom</Address2><CountrySubDivision>Nokorn Pathom</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Nonthaburi</Address2><CountrySubDivision>Nonthaburi</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Phang Nga</Address2><CountrySubDivision>Phang Nga</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Phatthalung</Address2><CountrySubDivision>Phatthalung</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Phayao</Address2><CountrySubDivision>Phayao</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Phichit</Address2><CountrySubDivision>Phichit</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Phitsanulok</Address2><CountrySubDivision>Phitsanulok</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Phrae</Address2><CountrySubDivision>Phrae</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Phuket</Address2><CountrySubDivision>Phuket</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Prachuap Khiri Khan</Address2><CountrySubDivision>Prachuap Khiri Khan</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Ratchaburi</Address2><CountrySubDivision>Ratchaburi</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Rayong</Address2><CountrySubDivision>Rayong</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Roi Et</Address2><CountrySubDivision>Roi Et</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Samut Sakhon</Address2><CountrySubDivision>Samut Sakhon</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Samut songkhram</Address2><CountrySubDivision>Samut songkhram</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Satun</Address2><CountrySubDivision>Satun</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Sisaket</Address2><CountrySubDivision>Sisaket</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Suphanburi</Address2><CountrySubDivision>Suphanburi</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Surat Thani</Address2><CountrySubDivision>Surat Thani</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Surin</Address2><CountrySubDivision>Surin</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Tak</Address2><CountrySubDivision>Tak</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Trang</Address2><CountrySubDivision>Trang</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Ubon Ratchathani</Address2><CountrySubDivision>Ubon Ratchathani</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Udon Thani</Address2><CountrySubDivision>Udon Thani</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Uthaithani</Address2><CountrySubDivision>Uthaithani</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Maung</Address1><Address2>Uttaradit</Address2><CountrySubDivision>Uttaradit</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Muang</Address1><Address2>Khon Kaen</Address2><CountrySubDivision>Khon Kaen</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Muang</Address1><Address2>Nakhorn Phanom</Address2><CountrySubDivision>Nakhorn Phanom</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Research Site</Name><Address1>Muang</Address1><Address2>Nong Khai</Address2><CountrySubDivision>Nong Khai</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hypercholesterolemia</Disease><PatientSegments><PatientSegment><PatientSegment id="7780">Subjects with Risk Factors for Coronary Heart Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7789">Subjects on Lipid Lowering Therapy</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Lipid metabolism disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="11319">Subjects with Risk Factors for Coronary Heart Disease(CHD)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00684151</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lipid metabolism disorder" id="23051"><Endpoint>Assessment of Low-Density Lipoprotein (LDL)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hypercholesterolemia" id="23916"><Endpoint>Assessment of Low-Density Lipoprotein (LDL)</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lipid metabolism disorder" id="20010"><Criterion>Subjects with Dyslipidemia</Criterion></Inclusion><Inclusion disease="Lipid metabolism disorder" id="20031"><Criterion>Subjects with Risk Factors for Coronary Heart Disease (CHD)</Criterion></Inclusion><Inclusion disease="Lipid metabolism disorder" id="20047"><Criterion>Subjects with History of Lipid Lowering Medication</Criterion></Inclusion><Inclusion disease="Hypercholesterolemia" id="20885"><Criterion>Subjects with Risk Factors for Coronary Heart Disease (CHD)</Criterion></Inclusion><Inclusion disease="Hypercholesterolemia" id="20899"><Criterion>Subjects with Acceptable Lipid Profile</Criterion></Inclusion><Inclusion disease="Hypercholesterolemia" id="20901"><Criterion>Subjects with History of Lipid Lowering Medication</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lipid metabolism disorder" id="17709"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Lipid metabolism disorder" id="17710">Subjects with coronary heart disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lipid metabolism disorder" id="17721"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hypercholesterolemia" id="18576"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Hypercholesterolemia" id="18577">Subjects with coronary heart disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hypercholesterolemia" id="18588"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2009-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>9.06 Months</EnrollmentPeriod><EnrollmentRate>136.87 Patients/Month</EnrollmentRate><DateFirstReceived>2008-05-22T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="218728"><TitleDisplay>Effect of High Doses of Radiation on Bone Structure and Metabolism</TitleDisplay><TitleOfficial>Pilot Study of the Effect of High Doses of Radiation on Bone Metabolism and Structure in Patients Treated With Adjuvant Radiotherapy and Surgery for Sacral Tumors</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02323295</Identifier><Identifier type="Organisational Study">14-208</Identifier><Identifier type="Secondary Organisational">C06CA059267</Identifier></Identifiers><Indications><Indication id="1012">Bone tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="743" role="Therapeutic effect marker" type="Genomic;Proteomic">Osteocalcin</BiomarkerName><BiomarkerName id="2072" role="Therapeutic effect marker" type="Proteomic">Procollagen Type I N-terminal peptide</BiomarkerName><BiomarkerName id="2968" role="Therapeutic effect marker" type="Genomic;Proteomic">Tartrate-resistant acid phosphatase type 5</BiomarkerName><BiomarkerName id="3083" role="Therapeutic effect marker" type="Biochemical">Phosphate</BiomarkerName><BiomarkerName id="3374" role="Therapeutic effect marker" type="Physiological">Bone mineral density</BiomarkerName><BiomarkerName id="9573" role="Therapeutic effect marker" type="Structural (imaging)">Bones</BiomarkerName><BiomarkerName id="17640" role="Therapeutic effect marker" type="Structural (imaging)">Trabecular bone</BiomarkerName><BiomarkerName id="20660" role="Therapeutic effect marker" type="Physiological">Bone formation rate</BiomarkerName><BiomarkerName id="28018" role="Therapeutic effect marker" type="Biochemical">25-Hydroxyvitamin D 2</BiomarkerName><BiomarkerName id="30391" role="Therapeutic effect marker" type="Genomic;Proteomic">C-terminal telopeptide of collagen type I</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Radiation (72 to 77.4 Gy)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="21569" type="Company"><TargetEntity id="4296541778" type="organizationId">Massachusetts Gen Hosp Pooled Pnsin Tr</TargetEntity></SourceEntity><SourceEntity id="1012" type="ciIndication"><TargetEntity id="10005995" type="MEDDRA"></TargetEntity><TargetEntity id="D001859" type="MeSH"></TargetEntity><TargetEntity id="-1645837123" type="omicsDisease"></TargetEntity><TargetEntity id="579" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21569">Massachusetts General Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2015-07-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-07-31T00:00:00Z</DateEnd><DateChangeLast>2019-02-28T02:10:41Z</DateChangeLast><DateAdded>2014-12-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>jhschwab@partners.org</Email><Name>Joseph Schwab, MD</Name><Phone>617-632-2483</Phone></Contact><Contact type="Scientific contact"><Affiliation>Massachusetts General Hospital</Affiliation><Name>Joseph H. Schwab, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All laboratory tests that are a part of the eligibility criteria must be completed within 14 days prior to the date of registration. Diagnostic tests that are a part of the eligibility criteria must be performed within 30 days of the date of registration. Patients must meet the following criteria on screening examination to be eligible to participate in the study:&lt;ul&gt;&lt;li&gt;Study patients must have histologically confirmed primary malignant bone tumor in the sacrum for which surgery and radiation or radiation alone are planned&lt;/li&gt;&lt;li&gt;Age 18 years or older. In children under the age of 8 years, tetracycline derivatives have been reported to stain tooth enamel yellow color. These considerations lead us to exclude young persons under the age of 18 years from the study&lt;/li&gt;&lt;li&gt;Patients must have normal organ and marrow function as defined below:&lt;ul&gt;&lt;li&gt;Total bilirubin within normal institutional limits&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST) (SGOT)/Alanine-aminotransferase (ALT) (SGPT)&amp;lt; 2.5 x institutional upper limit of normal&lt;/li&gt;&lt;li&gt;Creatinine within normal institutional limits or creatinine clearance&amp;gt; 60 ml/min/1.73 m2 for patients with creatinine levels about institutional normal limit&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;The effects of tetracyclines and radiation used in computer tomography on the developing human fetus are known to be detrimental. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately&lt;/li&gt;&lt;li&gt;Patients must be able to read and understand English language and have the ability to understand and the willingness to sign a written informed consent document&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who exhibit any of the following conditions at screening will not be eligible for admission into the study:&lt;ul&gt;&lt;li&gt;Patients who have had surgery, chemotherapy, or radiotherapy of the sacrum prior to entering the study&lt;/li&gt;&lt;li&gt;History of allergic reactions attributed to compounds of similar chemical or biological composition to tetracyclines&lt;/li&gt;&lt;li&gt;Pregnant or nursing&lt;/li&gt;&lt;li&gt;Uncontrolled inter current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in Bone mineral density (Tb BMD): trabecular bone mineral density will be measured in mg/cm3 using volumetric Quantitative Computed Tomography (QCT) of L1, L2 and the vertebrae adjacent to the tumor</Description><Timeframe>Non-surgical arm: baseline, 3 months. Surgical arm: baseline, 9 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Anxiety: PROMIS Anxiety questionnaire will be used. Unit of measure will be a T-score</Description><Timeframe>Non-surgical arm: baseline, 7 weeks, approximately 5, 8, 14 months. Surgical arm: baseline, approximately 4, 6, 9, 15 months</Timeframe></Measure><Measure><Description>Bone formation rate (BRF/BS): tetracycline quadruple labeling method will be used and the unit of measure will be mm3/mm2/day</Description><Timeframe>Only surgical arm: the months after biopsies are taken during surgery (surgery is during week 4 and 5). These measurements will be done in batches so timeframe isn't clear</Timeframe></Measure><Measure><Description>Change in Bone mineral density distribution (BMDD): quantitative back scatter electron imaging will be used. BMDD is a frequency distribution of the calcium (Ca) content found in the bone sample</Description><Timeframe>Only in surgical arm: the week after the surgery, during witch the bone biopsies are taken (the surgeries are in week 4 and 5)</Timeframe></Measure><Measure><Description>Bone volume fraction (BV/TV): microscopic computer tomography (micro-CT) will be used and the unit of measure will be the fraction of bone volume/total volume in percentages</Description><Timeframe>Only in surgical arm: the week after the surgery, during witch the bone biopsies are taken (the surgeries are in week 4 and 5)</Timeframe></Measure><Measure><Description>Depression: PROMIS Depression questionnaire will be used. Unit of measure will be a T-score</Description><Timeframe>Non-surgical arm: baseline, 7 weeks, approximately 5, 8, 14 months. Surgical arm: baseline, approximately 4, 6, 9, 15 months</Timeframe></Measure><Measure><Description>Health Related Quality of Life: EuroQol-5D questionnaire will be used. Unit of measurement will be an Index Value</Description><Timeframe>Non-surgical arm: baseline, 7 weeks, approximately 5, 8, 14 months. Surgical arm: baseline, approximately 4, 6, 9, 15 months</Timeframe></Measure><Measure><Description>Mineral apposition rate (MAR): tetracycline quadruple labeling method will be used and the unit of measure will be mm/day</Description><Timeframe>Only surgical arm: the months after biopsies are taken during surgery (surgery is during week 4 and 5). These measurements will be done in batches so timeframe isn't clear</Timeframe></Measure><Measure><Description>Mineralization lag time (Mlt): tetracycline quadruple labeling method will be used and the unit of measure will be days</Description><Timeframe>Only surgical arm: the months after biopsies are taken during surgery (surgery is during week 4 and 5). These measurements will be done in batches so timeframe isn't clear</Timeframe></Measure><Measure><Description>Osteoblast number (N Ob/BPm): immunohistochemistry staining methods will be used and the unit of measure will be mm-1</Description><Timeframe>Only surgical arm: the weeks after biopsies are taken during surgery (surgery is during week 4 and 5)</Timeframe></Measure><Measure><Description>Osteoblast surface (Ob S/BS): immunohistochemistry staining methods will be used and the unit of measure will be mm-1</Description><Timeframe>Only surgical arm: the weeks after biopsies are taken during surgery (surgery is during week 4 and 5)</Timeframe></Measure><Measure><Description>Osteoclast number (N Oc/BPm): immunohistochemistry staining methods will be used and the unit of measure will be mm-1</Description><Timeframe>Only surgical arm: the weeks after biopsies are taken during surgery (surgery is during week 4 and 5)</Timeframe></Measure><Measure><Description>Osteoclast surface (Oc S/BS): immunohistochemistry staining methods will be used and the unit of measure will be percentages</Description><Timeframe>Only surgical arm: the weeks after biopsies are taken during surgery (surgery is during week 4 and 5)</Timeframe></Measure><Measure><Description>Pain Interference: PROMIS Pain Interference questionnaire will be used. Unit of measure will be a T-score</Description><Timeframe>Non-surgical arm: baseline, 7 weeks, approximately 5, 8 , 14 months. Surgical arm: baseline, approximately 4, 6, 9, 15 months</Timeframe></Measure><Measure><Description>Physical Function: patient Reported Outcomes Measurement Information System (PROMIS) Physical Function will be used. Unit of measure will be a T-score</Description><Timeframe>Non-surgical arm: baseline, 7 weeks, approximately 5, 8, 14 months; Surgical arm: baseline, approximately 4, 6, 9, 15 months</Timeframe></Measure><Measure><Description>Serum 25-hydroxycalciferol Vit D (25-OH VitD): indicators for systemic metabolism that can affect bone health, units reported in nmol/l</Description><Timeframe>Non-surgical arm: baseline, 3.5, 7 weeks, approximately 5, 8 months. Surgical arm: baseline, 5.5, 18.5 weeks, approximately 7, 10 months</Timeframe></Measure><Measure><Description>Serum C-Telopeptide (CTX): indicator for Bone Formation, units reported in nmol CTX/mmol creatinine</Description><Timeframe>Non-surgical arm: baseline, 3.5, 7 weeks, approximately 5, 8 months. Surgical arm: baseline, 5.5, 18.5 weeks, approximately 7, 10 months</Timeframe></Measure><Measure><Description>Serum Osteocalcin (OC): indicator for Bone Formation, units reported in ng/ml</Description><Timeframe>Non-surgical arm: baseline, 3.5, 7 weeks, approximately 5, 8 months. Surgical arm: baseline, 5.5, 18.5 weeks, approximately 7, 10 months</Timeframe></Measure><Measure><Description>Serum Phosphate (P): indicators for systemic metabolism that can affect bone health, units reported in mg/dl</Description><Timeframe>Non-surgical arm: baseline, 3.5, 7 weeks, approximately 5, 8 months. Surgical arm: baseline, 5.5, 18.5 weeks, approximately 7, 10 months</Timeframe></Measure><Measure><Description>Serum Tartrate-resistant acid phosphatase 5b (TRAP5b): indicator for Bone Formation, units reported in U/l</Description><Timeframe>Non-surgical arm: baseline, 3.5, 7 weeks, approximately 5, 8 months. Surgical arm: baseline, 5.5, 18.5 weeks, approximately 7, 10 months</Timeframe></Measure><Measure><Description>Serum Type 1 procollagen N-terminal (P1NP): indicator for systemic metabolism that can affect bone health, units reported in pg/ml</Description><Timeframe>Non-surgical arm: baseline, 3.5, 7 weeks, approximately 5, 8 months. Surgical arm: baseline, 5.5, 18.5 weeks, approximately 7, 10 months</Timeframe></Measure><Measure><Description>Trabecular Connectivity density (Conn.D): microscopic computer tomography (micro-CT) will be used and the unit of measure will be mm3</Description><Timeframe>Only in surgical arm: the week after the surgery, during witch the bone biopsies are taken (the surgeries are in week 4 and 5)</Timeframe></Measure><Measure><Description>Trabecular Structure model index (SMI): microscopic computer tomography (micro-CT) will be used. Structure model index indicates the relative prevalence of rods and plates in a 3d structure such as trabecular bone</Description><Timeframe>Only in surgical arm: the week after the surgery, during witch the bone biopsies are taken (the surgeries are in week 4 and 5)</Timeframe></Measure><Measure><Description>Trabecular bone pattern factor (TBPf): microscopic computer tomography (micro-CT) will be used and the unit of measure will be mm-1</Description><Timeframe>Only in surgical arm: the week after the surgery, during witch the bone biopsies are taken (the surgeries are in week 4 and 5)</Timeframe></Measure><Measure><Description>Trabecular number (Tb N): microscopic computer tomography (micro-CT) will be used and the unit of measure will be mm-1</Description><Timeframe>Only in surgical arm: the week after the surgery, during witch the bone biopsies are taken (the surgeries are in week 4 and 5)</Timeframe></Measure><Measure><Description>Trabecular separation (Tb Sp): microscopic computer tomography (micro-CT) will be used and the unit of measure will be mm</Description><Timeframe>Only in surgical arm: the week after the surgery, during witch the bone biopsies are taken (the surgeries are in week 4 and 5)</Timeframe></Measure><Measure><Description>Trabecular thickness (Tb Th): microscopic computer tomography (micro-CT) will be used and the unit of measure will be mm</Description><Timeframe>Only in surgical arm: the week after the surgery, during witch the bone biopsies are taken (the surgeries are in week 4 and 5)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study is designed to characterize the effects of high energy radiation on bone      breakdown, with a specific interest in reducing the rate of sacral fractures. In this research study, the investigators are looking to determine changes in      blood markers, bone density, and bone structure following radiation and to better understand      the reason for these changes.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be treated in two arms:&lt;br/&gt;Arm 1 (Non surgical-radiation only): for surgical candidates, the standard treatment will include pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient will be  treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). Non-surgical candidates will receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma).&lt;br/&gt;Arm 2 (Malignant tumor surgery and radiation): for surgical candidates, the standard treatment will include pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient will be  treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). Non-surgical candidates will receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma). Surgery  will  involve removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Massachusetts General Hospital</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>jhschwab@partners.org</Email><Name>Joseph Schwab, MD</Name><Phone>617-643-2483</Phone></Contact><Contact type="Facility investigator"><Name>Joseph H. Schwab, MD</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Bone tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7951">Subjects with Resectable Bone Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02323295</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Bone tumor" id="46035"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Bone tumor" id="11494">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Bone tumor" id="11471"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Bone tumor" id="31904">Assessment by EuroQol (EQ-5D)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Bone tumor" id="11495"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bone tumor" id="11524"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bone tumor" id="11525"><Endpoint>Assessment of Physical Examination</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bone tumor" id="46035"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Bone tumor" id="11494">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Bone tumor" id="7118"><Criterion>Subjects with Resectable Bone Cancer</Criterion></Inclusion><Inclusion disease="Bone tumor" id="7141"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="7146">Subjects with history of anti-cancer radiotherapy</SubCriterion><SubCriterion disease="Bone tumor" id="7147">Subjects with history of surgery/procedure for bone cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bone tumor" id="7151"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="7152">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Bone tumor" id="7153">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bone tumor" id="7158"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="7163">Subjects able to communicate in the language specified in the protocol</SubCriterion><SubCriterion disease="Bone tumor" id="7167">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bone tumor" id="7179"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Bone tumor" id="34045"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="7154">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bone tumor" id="34126"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="7168">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bone tumor" id="34435"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="7162">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Bone tumor" id="8740"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Bone tumor" id="8741"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Bone tumor" id="8759"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="8764">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bone tumor" id="8767"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="8768">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bone tumor" id="8779"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="8792">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bone tumor" id="27779"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Bone tumor" id="8784">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-07-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-11-21T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-12-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-04-21T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="273131"><TitleDisplay>The Healthy Weigh Study</TitleDisplay><TitleOfficial>A Randomized, Controlled Trial of Incentives Versus Environmental Strategies for Weight Loss</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02878343</Identifier><Identifier type="Organisational Study">821428</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Disease marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Environmental strategies</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Incentives</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Usual care</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20658" type="Company"><TargetEntity id="5000724109" type="organizationId">University of Pennsylvania</TargetEntity></SourceEntity><SourceEntity id="26857" type="Company"><TargetEntity id="4296788697" type="organizationId">Centers For Disease Control And Prevention</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20658">University of Pennsylvania</Company></CompaniesSponsor><CompaniesCollaborator><Company id="26857">Centers for Disease Control and Prevention</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Factorial Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>344</PatientCountEnrollment><DateStart>2015-04-30T00:00:00Z</DateStart><DateEnd type="actual">2018-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-12T16:28:42Z</DateChangeLast><DateAdded>2017-03-22T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>The University of Pennsylvania</Affiliation><Name>Karen Glanz, PhD, MPH</Name></Contact><Contact type="Scientific contact"><Affiliation>The University of Pennsylvania</Affiliation><Name>Kevin Volpp, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Men and women&amp;gt; 18 years  of age&lt;/li&gt;&lt;li&gt;Full-time or part-time employees at Southeastern Pennsylvania Transportation Authority , Independence Blue Cross, or the City of Philadelphia&lt;/li&gt;&lt;li&gt;BMI of 30 to 55 kg/m2&lt;/li&gt;&lt;li&gt;Participants must receive their health benefits from Independence Blue Cross; one of our partners in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Unstable heart disease, uncontrolled hypertension, kidney disease, and other serious chronic illness (eg,  transplant recipient, terminal illness)&lt;/li&gt;&lt;li&gt;Substance abuse; bulimia nervosa or related behaviors; or diabetes medication other than metformin&lt;/li&gt;&lt;li&gt;Pregnancy or breast feeding&lt;/li&gt;&lt;li&gt;Contraindications to counseling about diet, physical activity, or weight reduction&lt;/li&gt;&lt;li&gt;Unstable mental illness&lt;/li&gt;&lt;li&gt;Individuals unable to read consent forms or fill out surveys in English will be excluded&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean weight change: change in mean weight (lbs.) from baseline to 18 months</Description><Timeframe>Baseline to 18 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Cost effectiveness analysis for intervention arms: costs (USD) to implement the intervention arms will be analyzed, relative to effectiveness. Fixed and variable costs will include, but are not limited to, administrative costs of the program, incentive payments, personnel costs, and medical expenditures</Description><Timeframe>Baseline to 18 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was designed to  evaluate the comparative effectiveness of behavioral economic financial      incentives and environmental strategies, separately and together, in achieving initial      weight loss and maintenance of weight loss, in obese employee populations. &lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would be a  four-arm randomized controlled trial in which 344 employees of the City      of Philadelphia, Independence Blue Cross, and South Eastern Pennsylvania Transportation      Authority with initial Body Mass Index of 30 would be randomized to receive one of the      following: &lt;br/&gt;Daily lottery type incentives tied to achievement of weight loss goals      (incentive arm).&lt;br/&gt;Individually tailored environmental strategies around food intake and      physical activity (environmental arm).&lt;br/&gt;A combination of incentives and environmental      strategies (combined arm)&lt;br/&gt;Standard employee wellness benefits and weigh-ins every 6      months (control arm). &lt;br/&gt;Phase I of the study (first 6 months) would focus on weight loss. Phase      II (months 7 to 18) would focus on continued weight loss or maintenance for those who choose to      maintain weight loss as opposed to continuing to try to lose weight.  Phase III (months      19 to 24) would provide a period of post-intervention follow-up to measure sustainability of      effects.&lt;/para&gt;&lt;para&gt;Analysis Plan 11.1: Statistical Considerations Descriptive analyses Investigators would produce data summaries regularly using frequencies for categorical variables and means, medians, and ranges for continuous variables. Investigators would assess data quality and examine distributional assumptions with graphical methods. To evaluate balance among groups achieved by randomization,Investigators would compare baseline values of all variables across the 4 arms using appropriate tests.&lt;br/&gt;General procedures All primary analyses would be on an intent-to-treat basis including each participant in the group to which s/hewasrandomized, regardless of adherence to the assigned strategy. Given the high rates of missing data typical of weight loss studies, handling of missing datawasan important issue. Primary analyses would use multiple imputation for the missing in-person weight outcome at 18 months, using the randomization strata (sex, employer, initial BMI), study arm and other baseline variables as predictors in the imputation model. Baseline variables would include age, race, income, education, marital status, household size, physical activities, eating behavior index, stages of change, SF-36 General Health, and baseline weight. Sensitivity analyses would be performed with imputation models that also use post-baseline data, , and recent weight loss trend before drop out, as well as an analysis that assumes that any participants for whom follow-up weight loss data are unavailable have had their weight return to baseline (weight at beginning of Pre Phase). Within each arm, this last assumptionwaslikely to be conservative but this may not be the case in inter-arm comparisons, depending on the dropout rates in the different arms and true follow-up weights of the dropouts. Thus, a key secondary analysis would consider the effect of differential dropout among the treatment arms. For this analysis, methods that address potential patterns of MNAR may be considered in the missing data imputation, such as pattern mixture models as appropriate. Finally,Investigatorswould also consider a per-protocol type analysis, which examines the difference in the intervention arms in the complete case data.&lt;br/&gt;Efficacy Analyses All hypotheses would be tested using two-sided, 0.05-level tests unless otherwise specified (notably the Holm testing approach would be used for the five primary hypotheses in Specific Aims 1-4). The primary analyses would be an unadjusted intent-to-treat analyses, using a t-test for differences in weight change from baseline to 18 months, as measured by the in-person weight, between each intervention group and the control group, and the combined compared to each single intervention, applying the Holm p-value correction for multiple comparisons testing. If weight change appears to be non-normally distributed in the blinded data,Investigatorswould find an appropriate. Missing data would be handled as described above.&lt;br/&gt;Weight change between baseline and 18 months, with 95% confidence intervals (CIs), would be estimated for comparison with adjusted analyses. Investigators would estimate regression models adjusted for the stratification variables (sex, employer, initial BMI) and other participant characteristics factors including age, race, income, and education.Investigatorswould evaluate the evidence of confounding for other baseline variables (baseline weight, marital status, household size, physical activities- i.e total minutes of MVPA+walking/week, eating behavior index, stages of change, SF-36 General Health) using change in estimate criterion (10%).Investigators would fit exploratory models of the repeated weight measurements that incorporate time as a polynomial function or using visit-specific indicator variables to determine the most parsimonious model that adequately describes the observed patterns, as necessary. Models would be built separately for the in-person and at home weight data. Models using the at-home weight data would be considered only as potential exploratory analyses comparing the 3 intervention arms, since at-home weights are not available for the control arm. Investigators would investigate random-effects models that allow for baseline individual variability as well as variability in the changes in weights over time; an example was the following: E(weightij) = beta0 +beta1Timej + beta2Groupi+ beta 3Xi + b0i + b1i Timej, where i indicates subject, j indicates assessment times, the parameters are fixed effects linking time, a treatment group vector, and a vector of other demographic or clinical covariates Xi to the outcomes, and b0i and b1i are random intercept and slope effects. Tests for significance of random effects would use likelihood ratio tests for nested models; Investigators would compare models with different random effects structures using the maximized log-likelihoods and the Akaike Information Criterion (AIC).Investigators would apply standard diagnostic techniques to assess model adequacy. Investigators would use treatment by time interactions to assess whether the rate of change in weight differs by intervention arm. Investigators hypothesize that incentives may be more effective among lower income individuals and would evaluate this using interaction terms of income with treatment group. Investigators would explore differential effects by race and education and baseline levels of intrinsic motivation and stages of change. Investigators would also consider other potential mediators, such as the home food and activity environment. To assess the sensitivity of treatment effect estimates to missing data, Investigators mayfit hierarchical or mixed effects models with and without accounting for informative missing data.&lt;br/&gt;For Specific Aim 5,Investigators would consider appropriate methods for cost effective analysis such as the models proposed below. Investigators would assess the costs of each of the intervention arms from both the employer and social perspective and compare the cost differences between each arm relative to the effectiveness measured by incremental weight loss achieved. The principal incremental cost-effectiveness ratios between intervention and control arms would be from the employer's perspective andInvestigators would compare costs during the intervention from baseline to 18 months per unit change in weight. Secondary analyses may also 1) evaluate this same ratio but use either 6 months post- intervention data (24 month visit) or 12 months of intervention data (12 month visit) and 2) evaluate these 2 ratios using a limited social perspective. Cost models would use a generalized linear model with a log link and gamma family. Missing data strategies would parallel those described above. Investigators would assess sampling uncertainty for the comparison of costs and effects by calculating parametric 95% CIs for the cost per kg lost and acceptability curves. Standard errors and correlation of the difference in cost and effect would be derived using a bootstrap procedure.&lt;br/&gt;11.2 Power and Sample Size Considerations Investigators have designed the study with adequate power to detect differences in weight loss over an 18-month period. Our intervention should achieve its maximal impact in maintaining initial weight loss at the end of Phase II (month 18), when the incentive payments cease. To maintain the experiment-wide Type I error and guard against false conclusions of effectiveness, Investigators would use the Holm multiple comparisons adjustment for test the 5 primary comparisons in Specific Aims 1-4 . If the interventions are as effective as hypothesized, the proposed sample size maintains greater than 90% power to show significance for each of the three intervention arms compared to control and greater than 80% power to show significance for the combined intervention group compared to each of the two interventions alone.&lt;br/&gt;Itwasimportant to note that whileInvestigatorsoriginally planned to recruit 328 participants, a small subsetwasunable to successfully set up their Withings scales post randomization due to Wi-Fi connectivity issues. Therefore,Investigatorsincreased our target sample size by the number of people who were unable to connect their Withings scales to the Way To Health platform (16 additional subjects), bringing our recruitment total to 344 participants. The final statistical analysiswasadjusted for the stratification factors to account for any imbalances that may have occurred.Investigatorshave previously communicated this information to the IRB and the members of the Data Safety and Monitoring Board (DSMB), who approved this approach. The following information outlines our original power calculations and sample size considerations.&lt;br/&gt;We plan to recruit approximately one third of the participants required for the start of Phase I from each of our participating employers (IBC, SEPTA, and City of Philadelphia). Given the large number of potentially eligible employees,Investigatorscan, if needed, easily increase the proportion of participants from any of these employers to meet recruitment targets. Participants would be randomized to our 3 intervention groups and the control group using a 1:1 ratio for the intervention arms.Investigatorsbuilt in a margin of 20% of our original target sample size of 328 for potential attrition before the 18-month assessment, resulting in an expected 260 participants (65 per arm) who are available for analysis at the end of Phase II. This sample size would provide us with greater than 90% power to detect a difference in weight change between baseline and the 18-month weigh-in of 5 kg between each single intervention group and the control group (primary outcomes for Specific Aims 1-3) and 87% power to detect a 3 kg difference between the combined group and either the incentive or environmental strategies groups (Specific Aim 4). Namely,Investigatorswould have greater than 85% power for the 5 primary comparisons of interest for an expected weight change between months 0-18 of -8 kg, -5 kg and 0 kg in the combined, intervention and control groups, respectively (a net difference between single intervention and control groups of 5 kg, combined intervention and control groups of 8 kg, and 3kg between the single interventions and combined group) and assuming a standard deviation (S.D.) of weight loss of 5 kg.Investigatorswould also have greater than 80% power to detect a difference of 4.6 kg in weight change between single intervention and control groups and 7.3 kg between the combined and control groups (primary outcomes for Specific Aims 1-3), while maintaining approximately 80% power for a 2.7 kg difference between the combined and each single intervention (Specific Aim 4). For our secondary outcomes (Specific Aim 5),Investigatorswish to compare the cost differences between each arm relative to the effectiveness measured by incremental weight loss achieved.Investigatorswould calculate a point estimate of cost per kg of weight loss based on estimated inter-arm differences in weight loss and the incremental cost of the interventions, as described in C.3.d.ii.c. For weight loss at 18 months, given an expected incremental cost of $810 (incentives) and incremental weight loss of 5 kg, 328 participants provide 80% power to detect a cost per kg lost of $430 and greater than 90% power to detect a cost per kg lost of $575. This studywasprimarily a test of the efficacy of these interventions. Due to resource constraints and becauseInvestigatorsdo not yet know about intervention effectiveness,Investigators did not power this study based on cost effectiveness analyses. Estimated detectable costs per kg are a function of wide confidence intervals due to sample size.&lt;br/&gt;11.3 Measurement of effect: The goal of this analysis would be to assess relative weight loss in the intervention arms relative to control. For the principal cost-effectiveness analysis, measurement of incremental weight loss would be based on differences in weight between baseline and the 18 month visit; in secondary analyses it would be based on weight differences between baseline and 24 months and baseline and 12 months.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7734">Obese Class I Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7735">Obese Class II Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7736">Morbid Obesity(Class III) Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02878343</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20401">Assessment of weight loss</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="29627"><Endpoint>Health Economic Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="29628">Assessment of cost effectiveness</SubEndpoint><SubEndpoint disease="Obesity" id="29632">Cost of therapy/other health care costs</SubEndpoint><SubEndpoint disease="Obesity" id="29635">Health care resource utilization</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22429">Obese Class I Subjects</SubCriterion><SubCriterion disease="Obesity" id="22430">Obese Class II Subjects</SubCriterion><SubCriterion disease="Obesity" id="22433">Morbid Obesity(Class III) Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19678"><Criterion>Subjects with Protocol Specified BMI</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19682">Subjects with BMI&gt;30</SubCriterion><SubCriterion disease="Obesity" id="19684">Subjects with BMI&gt;40</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19790"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Obesity" id="34498"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19746">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34819"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19792">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15295"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15296">Subjects with eating disorders</SubCriterion><SubCriterion disease="Obesity" id="15401">Subjects co-morbid with alcohol and/or drug/substance abuse</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15299"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Obesity" id="15316"><Criterion>Subjects co-morbid with hypertension</Criterion></Exclusion><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15329">Subjects with chronic diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15346">Subjects on anti diabetic medication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15354"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15367">Subjects with inability to exercise or perform physical activity</SubCriterion><SubCriterion disease="Obesity" id="15381">Subjects not able to communicate/Lack of communication</SubCriterion><SubCriterion disease="Obesity" id="15393">Transplant subjects</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="24974"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15397">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="25598"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15385">Inability or unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-10-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2016-07-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-03-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-09-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="334408"><TitleDisplay>An observational study to assess the efficacy of stereotactic irradiation for patients with recurrent high-grade glioma and identify predictive factors of progression-free survival and overall survival following reirradiation</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="1108">Glioma</Indication></Indications><BiomarkerNames><BiomarkerName id="1289" role="Therapeutic effect marker" type="Structural (imaging)">Tumor mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fractionated stereotactic radiotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>stereotactic radiosurgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1162662" type="Company"><TargetEntity id="5063302904" type="organizationId">Gcs Institut Universitaire Du Cancer Oncopole</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"></TargetEntity><TargetEntity id="D005910" type="MeSH"></TargetEntity><TargetEntity id="-1503483999" type="omicsDisease"></TargetEntity><TargetEntity id="680" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1162662">University Institute Cancer Toulouse Oncopole</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TrialCategories><Category>Radiation therapy</Category></TrialCategories><PatientCountEnrollment>32</PatientCountEnrollment><PatientCountEvaluable>32</PatientCountEvaluable><DateChangeLast>2018-04-02T22:01:44Z</DateChangeLast><DateAdded>2018-04-02T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with recurrent brain high-grade glioma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Median progression-free survival (PFS)</Description></Measure><Measure><Description>Overall survival</Description></Measure><Measure><Description>Predictive factors of PFS and OS</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this observational study was to assess the efficacy of stereotactic irradiation for patients with recurrent high-grade glioma and identify predictive factors of progression-free survival and overall survival following reirradiation [&lt;ulink linkType="Reference" linkID="2018504"&gt;2018504&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2018, results were published. Median PFS was 3.3 months. Overall survival was 90.40 and 79.55% at 6 and 12 months, respectively. Based on univariate analysis, biological effective dose at isocenter &amp;lt;/= 76 Gy was a poor prognostic factor for both OS (83.33 versus 100% at 6 months, p = 0.032) and median PFS (2.7 versus 4.7 months, p = 0.025), as was gross tumor volume (GTV) above 1 cm3 for OS (86.15 versus 94.12% at 6 months, p = 0.043). Contact with the subventricular zone (SVZ) was also a poor prognostic factor for median PFS (2.3 versus 4.7 months, p = 0.002). Based on multivariate analysis, SVZ contact remained a poor prognostic factor for PFS (hazard ratio = 3.44, p = 0.021) [&lt;ulink linkType="Reference" linkID="2018504"&gt;2018504&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients treated with either single-dose (stereotactic radiosurgery) or fractionated stereotactic radiotherapy between April 2008 and October 2015 were evaluated in this study [&lt;ulink linkType="Reference" linkID="2018504"&gt;2018504&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-04-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="336040"><TitleDisplay>Accumbofrontal Tract Study in Two Populations of Patients With Anorexia Nervosa and Obsessional Compulsive Disorder and Healthy Volunteer</TitleDisplay><TitleOfficial>Multimodal MRI Study of Accumbofrontal Tract in Anorexia Nervosa and Obessional Compulsive Disorder: Search for Structural and Functional Changes Between Orbito-frontal Cortex and Accumbens Nucleus Subdivisions</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03496285</Identifier><Identifier type="Organisational Study">ACCUMBENS</Identifier><Identifier type="Trial Acronym">ACCUMBENS</Identifier></Identifiers><Indications><Indication id="24">Anorexia nervosa</Indication><Indication id="468">Obsessive compulsive disorder</Indication></Indications><BiomarkerNames><BiomarkerName id="8375" role="Disease marker" type="Structural (imaging)">Fractional anisotropy</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Multimodal MRI</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1047446" type="Company"><TargetEntity id="5035544416" type="organizationId">Centre Hospitalier Universitaire Poitiers</TargetEntity></SourceEntity><SourceEntity id="24" type="ciIndication"><TargetEntity id="F50.0" type="ICD10"></TargetEntity><TargetEntity id="307.1" type="ICD9"></TargetEntity><TargetEntity id="10002649" type="MEDDRA"></TargetEntity><TargetEntity id="D000856" type="MeSH"></TargetEntity><TargetEntity id="-558410060" type="omicsDisease"></TargetEntity><TargetEntity id="42" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="468" type="ciIndication"><TargetEntity id="F42" type="ICD10"></TargetEntity><TargetEntity id="10029898" type="MEDDRA"></TargetEntity><TargetEntity id="D009771" type="MeSH"></TargetEntity><TargetEntity id="-204041926" type="omicsDisease"></TargetEntity><TargetEntity id="34" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1047446">Centre Hospitalier Universitaire De Poitiers Etablissement D’Hospitalisation</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Diagnosis</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2018-05-02T00:00:00Z</DateStart><DateEnd type="estimated">2019-02-28T00:00:00Z</DateEnd><DateChangeLast>2018-10-14T00:50:48Z</DateChangeLast><DateAdded>2018-04-16T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>benoit.bataille@chu-poitiers.fr</Email><Name>Benoît BATAILLE</Name><Phone>05 49 44 45 85</Phone></Contact><Contact type="Public contact"><Email>christophe.boulloud@gmail.com</Email><Name>Christophe BOULLOUD</Name><Phone>05 49 44 45 85</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Female patients&lt;/li&gt;&lt;li&gt;Age between 18 and 65 years&lt;/li&gt;&lt;li&gt;Subjects free to give their written consent&lt;/li&gt;&lt;li&gt;For anorexia nervosa :&lt;ul&gt;&lt;li&gt;Patients meeting the diagnostic criteria for anorexia nervosa according to DSM5 (American Psychiatric Association): low weight (&amp;lt; 85% of expected weight for age and height), fear of gaining weight or becoming fat, distortion of body image, and amenorrhea for &gt; 3 months&lt;/li&gt;&lt;li&gt;Treatment with at least one antidepressant and one anxiolytic&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;For OCD:&lt;ul&gt;&lt;li&gt;Patients meeting the diagnostic criteria of OCDs according to DSM5 (American Psychiatric Association): presence of obsessions and/or compulsions, resulting in clinically significant suffering (loss of at least 1 h/day) or impairment at the social, occupational level or in another important area of life. These symptoms are not due to the physiological effects of a substance or a general medical condition and cannot be better explained by the symptoms of another psychiatric disorder&lt;/li&gt;&lt;li&gt;Patients with homogeneous OCD in obsession and compulsion&lt;/li&gt;&lt;li&gt;Normal weight compared to expected weight for age and height&lt;/li&gt;&lt;li&gt;Treatment with at least one antidepressant and one anxiolytic&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;For healthy volunteer:&lt;ul&gt;&lt;li&gt;Normal weight compared to expected weight for age and height&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Male&lt;/li&gt;&lt;li&gt;Age&amp;lt; 18  or &amp;gt; 65 years&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Absence of free and informed consent signature&lt;/li&gt;&lt;li&gt;Current processing by rTMS&lt;/li&gt;&lt;li&gt;Somatic intercurrent pathologies: neurological, cardiological, pneumological, renal, hepatic, endocrine, metabolic disorders&lt;/li&gt;&lt;li&gt;Mental retardation (WAIS-IV QI&amp;lt; 70)&lt;/li&gt;&lt;li&gt;Primary amenorrhea&lt;/li&gt;&lt;li&gt;Absolute contraindication or relative to the realization of a magnetic resonance imaging without injection of contrast medium&lt;/li&gt;&lt;li&gt;Old or intercurrent psychotic pathology&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Fractional Anisotropy (probabilistic tractography): evaluate the mean functional anisotropy value for fiber bundles connecting the orbito-frontal cortex and the nucleus accumbens</Description><Timeframe>20 min</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>BOLD Signal (resting state): evaluate the value of the BOLD-signal of the fiber bundles connecting the orbito-frontal cortex and the nucleus accumbens</Description><Timeframe>20 min</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objective of this      study will be to compare the structure and the connectivity of this tract in MRI with      diffusion sequences (DTI tractography) and resting-state, in three distinct populations of      anorexic patients, patients with OCD and healthy patients. The role of the accumbo-frontal      tract in the cortico-striato-hypothalamo-cortical circuit seems to be established. DTI      tractography will allow the measurement of functional anisotropy (FA), a parameter that      evaluates the diffusion of water molecules along the white matter fibers, and therefore the      potential alteration of the studied tract. Resting state sequences will allow to estimate the      BOLD signal and the functionality of the tract.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with anorexia nervosa, obsessional-compulsive disorder and healthy controls will undergo multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>CH Laborit</Name><Address1>Poitiers</Address1><Address3>86021</Address3><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>ghina.harika-germaneau@ch-poitiers.fr</Email><Name>HARIKA GERMANEAU</Name><Phone>0549445802</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Anxiety disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="7474">Subjects with Obsessive Compulsive Disorder</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="15222">Others</PatientSegment><SubSegments><SubSegment id="18723">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other psychiatric disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16686">Others</PatientSegment><SubSegments><SubSegment id="17331">Healthy Subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="18268">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="17235">Subjects with Anorexia Nervosa</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03496285</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anxiety disorder" id="10489"><Endpoint>Assessment of Brain Structure and Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other psychiatric disease" id="43479"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Anxiety disorder" id="44965"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Anxiety disorder" id="10489"><Endpoint>Assessment of Brain Structure and Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other psychiatric disease" id="43479"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Anxiety disorder" id="6531"><Criterion>Subjects with a Specific Anxiety Disorder</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6538">Subjects with obsessive compulsive disorder[OCD]</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="6540"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion></Inclusion><Inclusion disease="Anxiety disorder" id="6557"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Anxiety disorder" id="6601"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion></Inclusion><Inclusion disease="Anxiety disorder" id="6610"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6611">Subjects with history of anti depressants</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other psychiatric disease" id="33038"><Criterion>Subjects with eating disorders</Criterion><SubCriteria><SubCriterion disease="Other psychiatric disease" id="33216">Subjects with Anorexia Nervosa</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other psychiatric disease" id="34318"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other psychiatric disease" id="32987">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="34428"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6638">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="34519"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6636">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other psychiatric disease" id="34549"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Other psychiatric disease" id="32989">Subjects with protocol specified weight/BMI values</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other psychiatric disease" id="34646"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other psychiatric disease" id="32986">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other psychiatric disease" id="35529"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Other psychiatric disease" id="33135">Subjects meeting the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic critera for the specified disease</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Anxiety disorder" id="8194"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8196">Subjects co-morbid with metabolic diseases/disorders</SubCriterion><SubCriterion disease="Anxiety disorder" id="8201">Subjects co-morbid with respiratory disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8197"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="8198"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="8226"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8237">Subjects with history of transcranial magnetic stimulation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="8252"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8260">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other psychiatric disease" id="24026"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other psychiatric disease" id="24308"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="24911"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8261">Subjects with Hypersensitivity/Contraindication to MRI</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other psychiatric disease" id="24965"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other psychiatric disease" id="24499">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="25432"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8253">Subjects unable to provide informed consent/assent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other psychiatric disease" id="25621"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="26021"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="26076"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8199">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Anxiety disorder" id="26136"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Other psychiatric disease" id="26557"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Other psychiatric disease" id="29155"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="29353"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-01-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-04-05T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-04-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="348617"><TitleDisplay>Dietary Protein Intake And Rehabilitation From Anterior Cruciate Ligament Surgery</TitleDisplay><TitleOfficial>The Effects Of Providing Protein And Nutritional Guidance On Healing Times After ACL Surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03614351</Identifier><Identifier type="Organisational Study">IRB00046590</Identifier></Identifiers><Indications><Indication id="3754">Knee injury</Indication></Indications><BiomarkerNames><BiomarkerName id="19664" role="Therapeutic effect marker" type="Structural (imaging)">Thigh muscle</BiomarkerName><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Combat protein powder, MusclePharm</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Physical Therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Physical Therapy</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1158032" type="Company"><TargetEntity id="5013268180" type="organizationId">Wake Forest University Health Sciences</TargetEntity></SourceEntity><SourceEntity id="3754" type="ciIndication"><TargetEntity id="5599" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1158032">Wake Forest University Health Sciences, US</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2019-08-31T00:00:00Z</DateStart><DateEnd type="estimated">2021-08-31T00:00:00Z</DateEnd><DateChangeLast>2019-06-14T02:10:09Z</DateChangeLast><DateAdded>2018-08-14T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>gdmiller@wakehealth.edu</Email><Name>Gary Miller, Ph.D.</Name><Phone>(336) 758-1901</Phone></Contact><Contact type="Scientific contact"><Affiliation>Wake Forest University Health Sciences</Affiliation><Name>Gary Miller, Ph.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Participants with a complete ACL tear and received a hamstring autograft ACL repair surgery (within 8 months of injury) and plan to complete physical therapy and follow up treatment with WFBH at D1 outpatient rehabilitation&lt;/li&gt;&lt;li&gt;Subjects must have a smartphone capable of running the nutrition tracking app (My Fitness Pal)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects must not have other ligamentous involvement, or complications during the surgical procedure&lt;/li&gt;&lt;li&gt;They must not have had a concurrent meniscal repair (debridement is acceptable)&lt;/li&gt;&lt;li&gt;They must not have post-operative limitations that interfere with rehabilitation&lt;/li&gt;&lt;li&gt;Patients determined by the referring surgeon to be poor candidates for the study for any medical (including history of eating disorder, phenylketonuria, maple syrup urine disease, food allergies, lactose intolerance, kidney or liver disease) or other reasons that deem them inappropriate to complete the intervention (driving distance from facility, work schedule that prohibits therapy treatments, dietary restrictions) will be excluded&lt;/li&gt;&lt;li&gt;Females who are pregnant will not be permitted in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Percentage of individuals that complied with treatment/intervention: compliance among treatment group in meeting 2 g/kg protein goal as measured by protein tracking app and in protein supplements provided will be measured</Description><Timeframe>Up to 6 months</Timeframe></Measure><Measure><Description>Percentage of frequency individuals successfully used the protein tracking app: compliance in usage of protein tracking app will be recorded. The number of days they logged in and recorded their intake versus total potential days to provide % value of diet protein compliance</Description><Timeframe>Up to 6 months</Timeframe></Measure><Measure><Description>Percentage of physical therapy visits attended by individuals: compliance in physical therapy will be recorded</Description><Timeframe>Up to 6 months</Timeframe></Measure><Measure><Description>Percentage counseling sessions attended by individuals: compliance in attending nutritional counseling sessions will be recorded</Description><Timeframe>Up to 6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in muscle hypertrophy: depth of vastus medialis as measured at each nutritional advising appointment with counselor via ultrasound and thigh circumference</Description><Timeframe>Baseline and up to 6 month</Timeframe></Measure><Measure><Description>Change in strength in leg flexion and extension: strength in leg flexion and extension, as measured by Biodex machine</Description><Timeframe>Baseline and up to 6 month</Timeframe></Measure><Measure><Description>Single leg hop test: functional healing time based on single leg hop test. The distance the participant hopped on one leg will be recorded and measured in cm. This will be done three times and an average will be given</Description><Timeframe>Baseline and up to 6 month</Timeframe></Measure><Measure><Description>Six meter timed hop test: functional healing time based 6 m timed hop test. The time it took the participant to hop 6 m on foot will be measured and recorded</Description><Timeframe>Baseline and up to 6 month</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to evaluate the effects of providing protein and nutritional guidance on healing times after Anterior Cruciate Ligament (ACL)   surgery.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consists of two arms:&lt;br/&gt;Arm 1: participants will be randomized to the protein supplementation group, PROT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app. Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80 g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.&lt;br/&gt;Arm 2: participants will be randomized to the enhanced-care control group, CONT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app. Instructed not to alter their diet based on the app, and to continue to eat as they normally would.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Wake Forest Baptist Medical Center</Name><Address1>Winston-Salem</Address1><Address2>North Carolina</Address2><Address3>27157</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18266">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16631">Subjects with anterior cruciate ligament injury</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03614351</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other musculoskeletal disease" id="43039"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other musculoskeletal disease" id="42991"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="43038"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="43039"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46485"><Endpoint>Anthropometric Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other musculoskeletal disease" id="32681"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other musculoskeletal disease" id="34802"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="32739">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other musculoskeletal disease" id="35079"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other musculoskeletal disease" id="24023"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24089"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24093"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24185"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24962"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24043">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="25891"><Criterion>Immunocompromised Subjects</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="26901"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="27146"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="27918"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="29152"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2021-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-07-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-08-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-02-20T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="353498"><TitleDisplay>Comparison Between  iPro2 and LibrePro in Hemodialysis</TitleDisplay><TitleOfficial>Comparison of Accuracy Between  iPro2 and LibrePro in Patients on Hemodialysis</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000034162</Identifier></Identifiers><Indications><Indication id="97">Diabetes mellitus</Indication></Indications><BiomarkerNames><BiomarkerName id="1735" role="Disease marker" type="Biochemical">Glucose</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>LibrePro</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>continuous glucose monitoring</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>iPro2</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="27396" type="Company"><TargetEntity id="5035524139" type="organizationId">Kitasato University</TargetEntity></SourceEntity><SourceEntity id="97" type="ciIndication"><TargetEntity id="10012601" type="MEDDRA"></TargetEntity><TargetEntity id="D003920" type="MeSH"></TargetEntity><TargetEntity id="-203480060" type="omicsDisease"></TargetEntity><TargetEntity id="506" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="27396">Kitasato University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2018-09-12T00:00:00Z</DateStart><DateChangeLast>2018-09-18T10:48:50Z</DateChangeLast><DateAdded>2018-09-18T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Kitasato University School of Medicine ; Endocrinology, Diabetes and Metabolism
</Affiliation><Email>ahayashi@kitasato-u.ac.jp</Email><Name>Akinori Hayashi</Name><Phone>0427788111</Phone></Contact><Contact type="Scientific contact"><Affiliation>Kitasato University School of Medicine ; Endocrinology, Diabetes and Metabolism
</Affiliation><Email>ahayashi@kitasato-u.ac.jp</Email><Name>Akinori Hayashi</Name><Phone>0427788111</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients on hemodialysis agreed to this study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects disagreed to this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>MARD  (mean absolute relative difference)</Description></Measure><Measure><Description>Sensor glucose data</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Relationship between sensor glucose data and diabetic markers</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study is the comparison of accuracy between iPro2 and LibrePro in patients on hemodialysis. Safety and efficay will also be evaluated.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients on hemodialysis with/without diabetes will be enrolled in this trial. Patients will wear two kinds of continuous glucose monitoring devices (iPro2 and LibrePro).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Kitasato University School of Medicine; Endocrinology, Diabetes and Metabolism</Name><Address1>Sagamihara</Address1><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000034162</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="18118"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin dependent diabetes" id="18173"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="43972"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18118"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18173"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="43972"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Non-insulin dependent diabetes" id="1624"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Non-insulin dependent diabetes" id="1650"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint><OtherEndpoint disease="Insulin dependent diabetes" id="18160"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Insulin dependent diabetes" id="18210"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18245">Accuracy of the blood glucose meter</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="683"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="6693"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="652">Subjects received/scheduled for hemodialysis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin dependent diabetes" id="16345"><Criterion>Subjects scheduled to receive disease specific therapy</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35101"><Criterion>Subjects with Diabetes Mellitus</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Insulin dependent diabetes" id="25684"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13919">Subjects who are unwilling/unable to sign informed consent form</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="25685"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="1076">Subjects who are unwilling/unable to sign informed consent form</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-09-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="354514"><TitleDisplay>Cemented Versus Cementless TKA</TitleDisplay><TitleOfficial>Early Outcomes of Cemented Versus Cementless Total Knee Arthroplasty Using the Triathlon Knee</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03683992</Identifier><Identifier type="Organisational Study">201308057</Identifier></Identifiers><Indications><Indication id="3754">Knee injury</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Cemented total knee arthroplasty</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Cementless total knee arthroplasty</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Triathlon total knee system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1160134" type="Company"><TargetEntity id="5044186705" type="organizationId">Washington University Schoolof Medicine in ST Louis</TargetEntity></SourceEntity><SourceEntity id="3754" type="ciIndication"><TargetEntity id="5599" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1160134">Washington University School of Medicine, US</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>150</PatientCountEnrollment><DateStart>2013-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2023-12-01T00:00:00Z</DateEnd><DateChangeLast>2018-10-20T06:03:37Z</DateChangeLast><DateAdded>2018-09-27T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Washington University School of Medicine</Affiliation><Name>Dr. Ryan Nunley</Name></Contact><Contact type="Public contact"><Affiliation>Washington University School of Medicine</Affiliation><Name>Dr. Robert Barrack</Name></Contact><Contact type="Public contact"><Affiliation>Washington University School of Medicine</Affiliation><Name>Dr. Denis Nam</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who qualify for a cementless primary total knee arthroplasty&lt;/li&gt;&lt;li&gt;Aged between 18  to 75 years&lt;/li&gt;&lt;li&gt;Willing to be randomized&lt;/li&gt;&lt;li&gt;Willing to sign informed consent&lt;/li&gt;&lt;li&gt;Willing to return for all follow-up visits&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with inflammatory arthritis&lt;/li&gt;&lt;li&gt;BMI&amp;lt;/= 40 &lt;/li&gt;&lt;li&gt;Patient with an active infection or suspected infection in the operative joint&lt;/li&gt;&lt;li&gt;The absolute and relative contraindications stated in the FDA cleared labeling for the device&lt;/li&gt;&lt;li&gt;Patients who have undergone osteotomy&lt;/li&gt;&lt;li&gt;Patients who have had previous patella fracture or surgery&lt;/li&gt;&lt;li&gt;Patients who have had previous healed tibia or femur fractures&lt;/li&gt;&lt;li&gt;Patients who have had previous knee or hip replacement surgery on the ipsilateral side&lt;/li&gt;&lt;li&gt;Patients who require patellar resurfacing&lt;/li&gt;&lt;li&gt;Patients with major medical/muscular/orthopedic deformities&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Difference in tourniquet time: tourniquet time will be recorded for each patient during surgery to see if there is a difference between tourniquet time between patients who are receiving cemented versus cementless</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Difference in functional pain score: patients will fill out a visual analog scale at 6 weeks, one year, two years to determine if there is a difference between functional pain score between cemented versus cementless</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>EQ-5D: EQ-5D questionnaire will be completed preoperatively, 6 weeks, one year, and two years. Subscales are summed together to compute total score</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Forgotten joint score: forgotten join score questionnaire will be completed preoperatively, 6 weeks, one year, and two years.Subscales are summed together to compute total score</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Oxford knee score: oxford knee score questionnaire will be completed preoperatively, 6 weeks, one year, and two years. Subscales are summed together to compute total score</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>SF-12 questionnaire: SF-12 questionnaire will be completed preoperatively, 6 weeks, one year, and two years. Subscales are summed together to compute total score</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>UCLA Activity score: UCLA questionnaire will be completed preoperatively, 6 weeks, one year, and two years. Subscales are summed together to compute total score</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Knee society score: knee society score questionnaire will be completed preoperatively, 6 weeks, one year, and two years.Subscales are summed together to compute total score</Description><Timeframe>Two years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study  will  compare cemented and cementless versions of the Triathlon      total knee arthroplasty/replacement (TKA) in terms of clinical outcomes, perioperative      course, and outcome scores including function and patient satisfaction.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who will present to the clinical practices of Dr Ryan Nunley, Dr Robert Barrack, or Dr      Denis Nam and aged between 18 to 75 years,  who will be suitable  for primary TKA , will be screened for eligibility and      invited to participate. Once enrolled, patients will be randomized (1 : 1) to either receive      a cemented or cementless Triathlon TKA. Data collected for the study will include standard-of-care clinical and radiographic evaluations collected during office visits and surgery, as      well as study-specific patient questionnaires.  Clinical, radiographic and questionnaire data      will be collected pre-operatively, at the time of surgery, and at 6 weeks, 6 months, one year      and beyond, and two years and beyond post-operatively. &lt;/para&gt;&lt;para&gt;Patients will complete the following      outcomes questionnaires preoperatively: new knee society score, oxford knee score, UCLA      activity score, SF-12, and EQ-5D. The following questionnaires will be collected at 4 to      6 weeks, 6 months, one year and beyond, and two years and beyond postoperatively: new      knee society score, forgotten joint score, Washington University knee satisfaction and      function questionnaire, oxford knee score, UCLA activity score, SF-12, and EQ-5D, and a pain      drawing. In addition, a pain diary with a pain Visual Analog Scale (VAS) will be assessed      once daily at home for 6 weeks after surgery.&lt;/para&gt;&lt;para&gt;Patients will be randomized to recieve either cemented or cementless knee implant by using the device, Triathlon total knee system and followed-up for two years.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16682">Others</PatientSegment><SubSegments><SubSegment id="18686">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03683992</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other musculoskeletal disease" id="42991"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other musculoskeletal disease" id="42991"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46368"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46383"><Endpoint>Assessment of Other Measures of Pain Quality</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other musculoskeletal disease" id="46477"><Endpoint>Assessment by Global Assessment Scales</Endpoint><SubEndpoints><SubEndpoint disease="Other musculoskeletal disease" id="46375">Visual analogue scales (VAS) for local and general pain/overall disease activity</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other musculoskeletal disease" id="34307"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="32740">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other musculoskeletal disease" id="34632"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="32738">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other musculoskeletal disease" id="34802"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="32739">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other musculoskeletal disease" id="24023"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24183"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24185"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24186">Subjects with history/requiring hip replacement</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-12-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-09-19T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-09-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="364755"><TitleDisplay>Transnasal airway versu laryngeal mask airway in pediatric anesthesia for minor surgery: a randomized, single-blind, non-inferiority trial</TitleDisplay><TitleOfficial>Transnasal airway versu laryngeal mask airway in pediatric anesthesia for minor surgery: a randomized, single-blind, non-inferiority trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1800020320</Identifier></Identifiers><Indications><Indication id="19">Anesthesia</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2014" role="Therapeutic effect marker" type="Physiological">End-tidal carbon dioxide</BiomarkerName><BiomarkerName id="10157" role="Therapeutic effect marker" type="Structural (imaging)">Lung</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>laryngeal airway mask</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>transnasal airway mask</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1007090" type="Company"><TargetEntity id="5035524909" type="organizationId">Nanjing University</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"></TargetEntity><TargetEntity id="D000758" type="MeSH"></TargetEntity><TargetEntity id="-564538434" type="omicsDisease"></TargetEntity><TargetEntity id="23" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1007090">Nanjing University</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>160</PatientCountEnrollment><DateStart>2018-12-25T00:00:00Z</DateStart><DateEnd type="estimated">2019-02-25T00:00:00Z</DateEnd><DateChangeLast>2018-12-27T22:01:26Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Children’s Hospital of Nanjing Medical University</Affiliation><Email>839371131@qq.com</Email><Name>Zhan wenqiang</Name><Phone>+86 15152461019</Phone></Contact><Contact type="Scientific contact"><Affiliation>Children’s Hospital of Nanjing Medical University</Affiliation><Email>zhaoshishi1990@outlook.com</Email><Name>Zhao shishi</Name><Phone>+86 15158680162</Phone></Contact></Contacts><MeasuresOutcome><MeasuresPrimary><Measure><Description>Tidal volume per kilogram body weight</Description><Timeframe>Time out, skin incision, and ligation of hernia sac</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>End-tidal carbon dioxide</Description><Timeframe>Time out, skin incision, and ligation of hernia sac</Timeframe></Measure><Measure><Description>Minute ventilation</Description><Timeframe>Time out, skin incision, and ligation of hernia sac</Timeframe></Measure><Measure><Description>Heart rate</Description><Timeframe>Time out, skin incision, and ligation of hernia sac</Timeframe></Measure><Measure><Description>Time required for intubation</Description></Measure><Measure><Description>Resistance during intubation</Description></Measure><Measure><Description>Failure at first attempt</Description></Measure><Measure><Description>Leakage rate</Description></Measure><Measure><Description>Regurgitation and aspiration: adverse events</Description></Measure><Measure><Description>Gaseous distention: adverse events</Description></Measure><Measure><Description>Laryngeal stridor: adverse events</Description></Measure><Measure><Description>Blood staining risk: adverse events</Description></Measure><Measure><Description>Hoarseness: adverse events</Description></Measure><Measure><Description>Loosening of teeth: adverse events</Description></Measure><Measure><Description>Nausea: adverse events</Description></Measure><Measure><Description>Emesis: adverse events</Description></Measure><Measure><Description>Sore throat: adverse events</Description></Measure><Measure><Description>Rhinalgia: adverse events</Description></Measure><Measure><Description>Jaw pain: adverse events</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt; The objective of this study is to designe the transnasal airway (TNA) and compare TNA against LMA for ventilation effect and complication rate.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Anesthesia will be administered through either transnasal airway or laryngeal airway mask.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Children's Hospital of Nanjing Medical University</Name><Address2>Jiangsu</Address2><CountrySubDivision>Jiangsu</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1800020320</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="379350"><TitleDisplay>An observational study to investigate whether body composition metrics could predict drug toxicity occurrence in advanced soft tissue sarcoma patients treated with eribulin</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers></Identifiers><Indications><Indication id="3378">Soft tissue sarcoma</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Toxic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="118" role="Toxic effect marker" type="Genomic;Proteomic">Albumin</BiomarkerName><BiomarkerName id="1925" role="Toxic effect marker" type="Cellular">Neutrophils</BiomarkerName><BiomarkerName id="35314" role="Toxic effect marker" type="Structural (imaging)">Skeletal Muscle</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>eribulin mesylate</Name><Drug id="28773">eribulin mesylate</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="28773">eribulin mesylate</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1080760">The University of Tokyo Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="28773" type="Drug"><TargetEntity id="287199" type="siDrug">Eribulin mesilate</TargetEntity></SourceEntity><SourceEntity id="1080760" type="Company"><TargetEntity id="5039144350" type="organizationId">University of Tokyo Hospital</TargetEntity></SourceEntity><SourceEntity id="3378" type="ciIndication"><TargetEntity id="10041299" type="MEDDRA"></TargetEntity><TargetEntity id="3394" type="ORPHANET"></TargetEntity><TargetEntity id="1736" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1080760">The University of Tokyo Hospital</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1545">Anticancer</Class><Class id="2575">Microtubule inhibitor</Class><Class id="7293">Synergist</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><PatientCountEnrollment>23</PatientCountEnrollment><PatientCountEvaluable>23</PatientCountEvaluable><DateChangeLast>2019-05-07T22:01:22Z</DateChangeLast><DateAdded>2019-05-13T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with advanced soft tissue sarcoma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>The relationship of BCMs and other clinical factors was evaluated, and CART analysis used to develop classification models for risk groups of drug toxicity</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to investigate whether body composition metrics (BCM) could predict drug toxicity occurrence in advanced soft tissue sarcoma patients treated with &lt;ulink linkType="Drug" linkID="28773"&gt;eribulin&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="2148325"&gt;2148325&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2019, results were published. A total of 16 patients (69.6%) experienced any grade 3/4 toxicity. A total of 11 patients (47.8%) developed grade 4 hematologic toxicity, which was significantly higher in those with low skeletal muscle gauge (SMG) (p = 0.02) and low pretreatment neutrophil count (p = 0.0002). A total of six patients (26.1%) had grade 3/4 non-hematologic toxicity and was higher in those with low SMG (p = 0.004), and low serum albumin level (p = 0.02). A total of five patients with high BMI (p = 0.03) experienced febrile neutropenia and low pretreatment neutrophil count (p = 0.02). CART analysis classified three risk groups, and area under the receiver operating characteristic curve (AUROCC) was 0.92, 0.88, 0.92 in grade 4 hematologic AE, grade /4 non-hematologic AE, febrile neutropenia, respectively [&lt;ulink linkType="Reference" linkID="2148325"&gt;2148325&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients treated with eribulin between March 2016 and April 2018 were evaluated in this study [&lt;ulink linkType="Reference" linkID="2148325"&gt;2148325&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>eribulin mesylate</Name><Drug id="28773">eribulin mesylate</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="142">Hematological disease</Indication></AdverseEvent><AdverseEvent><Indication id="3795">Febrile neutropenia</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries></TrialRegistries><OutcomeMeasureTerms></OutcomeMeasureTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-05-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>